Newsroom

CHICAGO--(BUSINESS WIRE)--Northern Trust will provide fund administration and other services to Moorstone, which invests in the global commodity supply chain....

RALEIGH, N.C.--(BUSINESS WIRE)--Convenience retail has long treated loyalty as a numbers game: lower the price, raise the frequency. But new national research from Vontier (NYSE: VNT) suggests something deeper is shaping American behavior at the pump and in the store. For the industry’s most frequent visitors, loyalty looks less like economics and more like familiarity. A national survey of over 600 US drivers reveals a clear divide. Casual drivers still shop transactionally. But the 24% who st...

BELLEVUE, Wash.--(BUSINESS WIRE)--Acumatica Cloud ERP today introduced its 2026 R1 product enhancements for professional services and field service organizations, including expanded AI capabilities, enhanced reporting tools, and new collaboration features to help mid-market businesses operate efficiently and make faster, data-driven decisions. As companies expand service offerings to drive revenue and strengthen customer relationships, many find that legacy systems struggle to scale, negatively...

LAKE GENEVA, Wis.--(BUSINESS WIRE)--Grand Geneva Resort & Spa, the award-winning, AAA Four-Diamond all-seasons resort, offers a first look at Wee Nip, its new 11-hole short course opening on May 19, 2026. Wee Nip introduces a relaxed, social way to experience golf at the resort. Designed by award-winning Dusenberry Design, Wee Nip is an inviting yet thoughtfully challenging short course created for golfers of all skill levels. Combining creativity, strategy and fun, the course features hole...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Lakeland Industries, Inc. (“Lakeland” or the “Company”) (NASDAQ:LAKE) investors of the April 24, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Lakeland securities between December 1, 2023 through December 9, 2025 (“the Class Period”). Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the liti...

OAKLAND, Calif.--(BUSINESS WIRE)--Fivetran, the data foundation for AI, today released “The enterprise data infrastructure benchmark report 2026,” revealing that fragile data pipelines are delaying analytics and AI initiatives while exposing large enterprises to significant operational lost revenue potential. Nearly 97% of senior data and technology leaders surveyed said pipeline failures have slowed analytics or AI programs, underscoring reliability as a growing constraint on enterprise AI suc...

HOUSTON--(BUSINESS WIRE)--As K-12 schools face growing scrutiny around how student wellbeing concerns are identified, documented, and addressed, Raptor Technologies® today announced an advancement of StudentSafe™, strengthening its industry-leading threat assessment capabilities while expanding the platform to support earlier, more consistent responses to concerns such as bullying, harassment, suicide risk, and other early warning signs. StudentSafe is designed to help schools act sooner—before...

LONDON--(BUSINESS WIRE)--ITRS unveils agentic AI capabilities built for mission-critical, regulated IT operations...

GREENWICH, Conn.--(BUSINESS WIRE)--Forward Consumer Partners (“Forward” or the “Firm”), a private investment firm focused on branded consumer products, today announces the successful closing of Forward Fund II (“Fund II”) at its $500 million hard cap. Launched in December 2025 and closed in March 2026, Fund II was significantly oversubscribed with commitments from a diverse base of respected global investors. Forward held a single close for Fund II and did not work with a placement agent. The F...

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with inclusion body myositis (IBM). IBM is a rare, debilitating and relentlessly progressive chronic autoimmune disease that currentl...